Anti Neprilysin Drugs Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Anti-neprilysin drugs are therapeutics designed to inhibit the neprilysin enzyme, an approach best known through sacubitril, which is combined with the ARB valsartan (as LCZ696, brand name Entresto) to treat chronic heart failure. The market's foundation is built around small-molecule inhibitors, while biologics such as monoclonal antibodies and peptides, plus dual-target candidates (e.g., combined ACE/NEP and endothelin-converting enzyme/NEP inhibitors), represent the next wave of development. Sacubitril/valsartan dominates revenue, while pipeline assets such as TD-0714, STR-324, PL-265, and LHW-090 are extending indications into acute heart failure, cancer pain, hypertension, and Alzheimer's disease.

• •Market valued at approximately USD 1.38 billion in 2025.
• •Forecast compound annual growth rate of about 4.63% through 2031.
• •Sacubitril/valsartan is the cornerstone commercial product, with diverse small-molecule and biologic candidates in the pipeline.

Rising prevalence of heart failure, particularly HFrEF and acute decompensated HF, is the single largest demand driver, supported by clinical guideline endorsement of sacubitril/valsartan. Expanding evidence that neprilysin modulates amyloid-beta clearance is opening a sizable opportunity in Alzheimer's disease. Aging populations in North America, Europe, and parts of Asia, alongside growing reimbursement coverage for ARNI (angiotensin receptor-neprilysin inhibitor) therapy, continue to lift prescription volumes.

• •Heart failure remains the dominant indication, with LCZ696 embedded in major cardiology guidelines.
• •Neprilysin's link to amyloid-beta metabolism is attracting research investment for Alzheimer's applications.
• •Demographic aging and improved diagnosis of cardiovascular disease support sustained prescription growth.

By drug type, the market splits into small-molecule inhibitors (the largest segment, anchored by sacubitril), biologic antibodies and peptides, and dual-target candidates such as ACE/NEP and ECE/NEP compounds. By indication, cardiovascular uses lead, with oncology pain, hypertension, and neurodegenerative disease as emerging segments. By distribution channel, hospital and retail pharmacies handle the bulk of dispensing, supplemented by online pharmacies as digital health adoption grows.

• •North America leads revenue, driven by early adoption of sacubitril/valsartan and broad insurance coverage.
• •Europe follows, supported by ESC heart-failure guideline recommendations.
• •Asia-Pacific is the fastest-growing region, propelled by improving access in China, Japan, and India.

What are the recent trends and outlook?

The next several years will see diversification beyond sacubitril as biologic antibodies, peptide agents, and dual-mechanism candidates progress in clinical development. Loss of exclusivity for sacubitril/valsartan in Europe and the United States will likely accelerate price erosion, but volume growth in chronic heart failure and earlier-line use should cushion the impact. Long-term upside depends on whether neprilysin-based mechanisms can demonstrate clinically meaningful benefits in Alzheimer's disease and other neurodegenerative conditions.

• •Patent expirations are expected to trigger generic competition and price compression through the late 2020s.
• •Dual-target candidates and biologics are the most active innovation areas.
• •Success in Alzheimer's or cancer-pain indications could materially expand the market beyond its cardiovascular base.